PRESS RELEASE Digital speech biomarker company ki:elements has published validation results on the use of its ki:e speech biomarker for cognition (SB-C) in early Alzheimer’s
We are grateful to announce that we will soon be collaborating in a major new decentralized trial, funded by the Alzheimer Drug Discoveries Foundation (ADDF)
Today, clinical research on early Alzheimer’s Disease (AD) dementia relies on invasive procedures and extended cognitive examinations both for screening and within trial usage. With
Alzheimer’s disease (AD) affects speech and language (Cummings, Benson, Hill & Read, 1985). This can be caused by the disease affecting language as a neurocognitive
The term executive functions appears in many psychological contexts. Among other reasons, this reflects the fact that the term refers to a conglomerate of individual
Artificial intelligence has long since become part of our everyday lives. In many applications we are aware of the use of AI, in others we
Forgetfulness is one of the most important symptoms in many neurocognitive diseases and especially known from Alzheimer’s disease. Forgetting is generally considered to be a
In 2009, World MS Day was founded by the Multiple Sclerosis International Federation (MSIF). MSIF helps to raise awareness and to gain a deeper understanding
The National Schizophrenia Foundation (NSF) is a non-profit organisation founded in 1950 which declared May 24 as World Schizophrenia Day in honor of Dr. Philippe
Hallucinations are a positive symptom in schizophrenia and psychosis, the most common type of hallucinations are auditory hallucinations, where patients perceive a sound in the